| Serial Number | 98507838 |
| Word Mark | ELSA |
| Filing Date | Thursday, April 18, 2024 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, July 1, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 1, 2025 |
| Goods and Services | Pharmaceutical preparations for the treatment of central nervous system diseases, neuromuscular diseases, metabolic diseases, and diseases related to RNA processing and translation |
| Goods and Services | Biochemical research and development, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Biotechnology research, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Gene therapy research, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Pharmaceutical drug development services, namely, development and design of anti-sense oligonucleotides; Pharmaceutical products development, namely, development and design of anti-sense oligonucleotides; Pharmaceutical research and development, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of RNA-targeted drugs, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of nucleic acids, biologics, central nervous system diseases, metabolic diseases, and small molecule drugs, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of gene therapy, namely, using bioinformatics to develop knowledge of the RNA transcript splicing regulation machinery to improve efficacy; Research and development in the pharmaceutical and biotechnology fields, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines, namely, development and design of anti-sense oligonucleotides; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy, namely, development and design of anti-sense oligonucleotides |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, April 18, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, April 18, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Fosun Pharma USA Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08540 |
| Party Name | Fosun Pharma USA Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08540 |
| Event Date | Event Description |
| Thursday, April 18, 2024 | NEW APPLICATION ENTERED |
| Sunday, October 6, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, November 1, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, November 6, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, November 6, 2024 | NON-FINAL ACTION WRITTEN |
| Monday, January 27, 2025 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Monday, January 27, 2025 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Friday, April 18, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, November 6, 2024 | NON-FINAL ACTION E-MAILED |
| Friday, April 18, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, April 18, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, May 9, 2025 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Friday, May 9, 2025 | FINAL REFUSAL E-MAILED |
| Friday, May 9, 2025 | FINAL REFUSAL WRITTEN |
| Wednesday, May 14, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, May 14, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, May 30, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, June 25, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, July 1, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, July 1, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, May 14, 2025 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |